A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

  • End date
    Aug 17, 2022
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 12 January 2022
body mass index
type 2 diabetes mellitus


The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.

Condition Type 2 Diabetes
Treatment Placebo, Dulaglutide, LY3502970
Clinical Study IdentifierNCT05048719
SponsorEli Lilly and Company
Last Modified on12 January 2022


Yes No Not Sure

Inclusion Criteria

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1

Exclusion Criteria

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note